Taysha gene therapies to release second quarter 2022 financial results and host conference call and webcast on august 11

Dallas, aug. 09, 2022 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced that it will report its financial results for the second quarter ended june 30, 2022, and host a corporate update conference call and webcast on thursday, august 11, 2022, at 8:00 am eastern time.
TSHA Ratings Summary
TSHA Quant Ranking